LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Cerrado

Sector Salud

1.69 1.2

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.66

Máximo

1.69

Métricas clave
By Trading Economics
Ingresos	-51M
Ventas	540K 702K
BPA	-0.2
Margen de beneficio	-31,188.272
Empleados	285
EBITDA	-49M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+390 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-1.2M 510M
Apertura anterior	0.49
Cierre anterior	1.69

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

8 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

1.67 / 1.72 Soporte y Resistencia

Lexicon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 mar 2024, 12:57 UTC

Principales Movimientos del Mercado

Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

390% repunte

Estimación a 12 meses

Media 8.33 USD 390%

Máximo 10 USD

Mínimo 5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.67 / 1.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

8 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.